Pacira publishes positive two-year Phase 1 data for PCRX-201 gene therapy in knee osteoarthritis

Reuters2026/08/06 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pacira Biosciences reported publication of two-year Phase 1 results for PCRX-201, its investigational gene therapy for knee osteoarthritis.
Results were already presented via the journal publication, showing the single knee injection was generally well tolerated.
Exploratory measures indicated sustained improvement in pain, stiffness, function through two years among patients who stayed in follow-up.
Glucocorticoid pre-treatment appeared to improve tolerability and outcomes, shaping the ongoing Phase 2 ASCEND trial design.
Phase 2 ASCEND topline results remain on track for a first readout at year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pacira publishes positive two-year Phase 1 data for PCRX-201 gene therapy in knee osteoarthritis

You may also like

Crypto prices